Table 4

KRAS mutations and progression of preneoplastic lesions

MutationNumber that progressedaUnivariate OR (P)Multivariate OR (P)b
Baseline mutation3.76 (0.05)3.74 (0.04)
 Absent14.6% (20/137)
 Present39.1% (9/23)
Change of mutation status(0.038, P for trend = 0.014)(0.039, P for trend = 0.03)
 (−) baseline, (−) follow-up13.8% (17/123)1.01.0
 (−) baseline, (+) follow-up21.4% (3/14)1.7 (0.45)1.6 (0.45)
 (+) baseline, (−) follow-up35.0% (7/20)3.4 (0.02)3.3 (0.03)
 (+) baseline, (+) follow-up66.0% (2/3)12.4 (0.04)12.7 (0.04)
  • a Progression includes the following situations: atrophy→intestinal metaplasia (IM); within IM: small intestinal metaplasia (SIM)→colonic intestinal metaplasia (CIM).

  • b Adjusted for treatment.